In an adult with a single suspected seizure who has returned to baseline and has no focal neurologic deficits, abnormal imaging, or epileptiform activity on EEG, should levetiracetam (Keppra) be started?

Should You Start Keppra for a Suspected Seizure?

No, do not start levetiracetam (Keppra) for an adult with a single suspected seizure who has returned to baseline with no focal deficits, abnormal imaging, or epileptiform activity on EEG. The FDA-approved indication for levetiracetam is as adjunctive therapy in established epilepsy, not for seizure prophylaxis after a single unprovoked seizure 1. Current guidelines address treatment of status epilepticus and established epilepsy, but do not support prophylactic antiseizure medication after a single first seizure in the absence of high-risk features 2.

Key Clinical Distinctions

Single Suspected Seizure (Your Scenario)

• Levetiracetam is NOT indicated for prophylaxis after a single seizure in patients who have returned to baseline 1
• The FDA label specifies levetiracetam is approved only as adjunctive therapy in patients with established epilepsy (partial onset seizures, myoclonic seizures in juvenile myoclonic epilepsy, or primary generalized tonic-clonic seizures) 1
• Recent high-quality evidence from the SPRING trial showed no benefit of prophylactic levetiracetam in seizure-naive patients: 47% of patients on prophylactic levetiracetam had seizures within 12 months versus 41% without prophylaxis (odds ratio 1.25,95% CI 0.49-3.21, p=0.64) 3

Status Epilepticus (Different Scenario)

• If seizures are ongoing or recurrent without return to baseline, this represents status epilepticus requiring immediate treatment 2
• First-line: benzodiazepines for seizures lasting ≥5 minutes 4
• Second-line (after benzodiazepine failure): levetiracetam 30 mg/kg IV at 5 mg/kg/min is appropriate and achieves seizure cessation in 68-73% of cases 5, 4

Clinical Algorithm for Decision-Making

Step 1: Determine if this is truly a single resolved seizure

• Patient returned to baseline? → Consider observation without medication
• Ongoing seizure activity or multiple seizures without recovery? → This is status epilepticus; proceed to treatment

Step 2: Assess for high-risk features requiring neuroimaging and EEG

• Focal neurologic deficits present? 2
• Abnormal brain imaging (mass, stroke, hemorrhage)? 4
• Epileptiform activity on EEG? 2
• If any present: These suggest structural or epileptogenic substrate requiring neurology consultation, not empiric ED treatment

Step 3: Identify reversible causes before considering antiseizure medication

• Hypoglycemia, electrolyte disturbances, hypoxia 4
• CNS infection, acute stroke, intracranial hemorrhage 4
• Drug toxicity or alcohol withdrawal 4
• Treat the underlying cause rather than starting prophylactic antiseizure medication

Common Pitfalls to Avoid

Pitfall #1: Confusing prophylaxis with treatment of active seizures

• Levetiracetam has proven efficacy in status epilepticus (68-73% cessation rate) 5, but this does NOT translate to benefit for preventing future seizures after a single resolved event 3

Pitfall #2: Prescribing based on setting rather than indication

• Inpatient settings are associated with more non-recommended ASM prescriptions (RR 0.82,95% CI 0.75-0.89 for guideline-concordant prescribing) 6
• Emergency department prescribing patterns show no difference from outpatient settings 6
• The clinical scenario, not the location, should drive prescribing decisions

Pitfall #3: Assuming "suspected" seizure requires treatment

• Without witnessed seizure activity, epileptiform EEG, or recurrent events, the diagnosis remains uncertain
• Starting antiseizure medication exposes patients to potential adverse effects (behavioral changes, somnolence) without proven benefit 7, 8

When Levetiracetam IS Appropriate

Established epilepsy requiring adjunctive therapy:

• Partial onset seizures: Start 500 mg BID, titrate by 1000 mg/day every 2 weeks to maximum 3000 mg/day 1
• Myoclonic seizures (age ≥12 years): Start 500 mg BID, increase to 3000 mg/day over 2 weeks 1
• Primary generalized tonic-clonic seizures (age ≥6 years): Start 500 mg BID, titrate to 3000 mg/day 1

Status epilepticus refractory to benzodiazepines:

• Dose: 30 mg/kg IV at 5 mg/kg/min (maximum 2.5-3 g) 4
• Equivalent efficacy to valproate and fosphenytoin with superior safety profile 2, 4
• Minimal hypotension risk compared to phenytoin (which causes hypotension in ~12% of cases) 4

Evidence Strength and Nuances

The 2024 ACEP guideline provides Level A recommendations that fosphenytoin, levetiracetam, or valproate may be used with similar efficacy for status epilepticus after benzodiazepine failure 2. However, this applies only to active, ongoing seizures, not prophylaxis.

The SPRING randomized controlled trial (2026) specifically addressed your clinical question and found no evidence of benefit for prophylactic levetiracetam in seizure-naive glioma patients undergoing surgery, with similar 12-month seizure rates in both groups 3. While this studied a surgical population, it represents the highest-quality evidence against prophylactic use in seizure-naive patients.

Levetiracetam is frequently prescribed off-label for seizure prophylaxis despite lack of supporting evidence 3, likely due to its favorable safety profile (minimal drug interactions, no cytochrome P450 induction) 7, 8. However, safety does not equal indication—the absence of harm does not justify treatment without demonstrated benefit.